A clinical trial for the anti-flu drug Avigan as treatment against COVID-19 is to be discontinued due to difficulties in assessing the drug s efficacy following the spread of the highly transmissible Omicron variant, the maker said.
The study on the Oral Antivirals Market published by Fact.MR is a comprehensive analysis of the key factors that are likely to determine the growth of Automatic Cat Feeder Market in the upcoming years. Further, the study dives deep to investigate the micro and macro-economic parameters that are expected to influence.
Fujifilm makes huge investments in healthcare but will not ditch camera industry entirely Pavni Jain
Fujifilm is one of the biggest camera makers in the industry, yet the Covid-19 pandemic didn t allow it to make tracks. The company has two dedicated lines of cameras -one, digital cameras, and two, its instant photo system called instax. Even then, Fujifilm is unable to generate revenues from its imaging portfolio. Post coronavirus crunch, the company is investing heavily in pharmaceuticals rather than its camera business.
In a report coming in from Reuters, it is noted that Fujifilm is focusing on its drug ingredients business to drive future profits. Fujifilm Toyama Chemical Co. Ltd. announced a phase III clinical trial for its anti-influenza drug Avigan tablet, in Japan, a couple of months ago. The tablet targets patients infected with novel coronavirus infections.
Merck and AstraZeneca to start COVID-19 drug trials in Japan japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.